Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes
- PMID: 35430735
- PMCID: PMC9441281
- DOI: 10.1111/1475-6773.13990
Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes
Abstract
Objective: The objective is to estimate the take-up of the Medicare Part D Low-Income Subsidy (LIS) among Medicare beneficiaries with diabetes and examine differences in out-of-pocket costs and prescription drug use between LIS enrollees and LIS-eligible non-enrollees. The LIS reduces out-of-pocket drug costs for low-income beneficiaries; however, not all LIS-eligible individuals are enrolled. Take-up of the LIS, and consequences of forgoing this benefit among beneficiaries with diabetes, remains unknown.
Data sources: Health and Retirement Study linked to Medicare administrative data from 2008 to 2016.
Study design: We conducted two analyses among beneficiaries with diabetes. First, we estimated LIS take-up stratified by income (≤100% of the Federal Poverty Level [FPL] and >100% to ≤150% of FPL). Second, to assess the consequences of forgoing the LIS among near-poor beneficiaries (incomes >100% to ≤150% of FPL), we conducted propensity score-weighted regression analyses to compare out-of-pocket costs, the prescription drug use, and cost-related medication non-adherence among LIS enrollees and LIS-eligible non-enrollees.
Data collection/data extraction: N/A.
Principal findings: Among Medicare beneficiaries with diabetes, 68.1% of those with incomes >100% to ≤150% of FPL received the LIS, while 90.3% with incomes ≤100% of FPL received the LIS. Among near-poor beneficiaries, LIS-eligible non-enrollees incurred higher annual out-of-pocket drug spending ($518; 95 [in USD]% CI: $370 [in USD], $667 [in USD]; p < 0.001), filled 7.3 fewer prescriptions for diabetes, hypertension, and hyperlipidemia drugs (95% CI: -11.1, -3.5; p < 0.001), and were 8.9 percentage points more likely to report skipping drugs due to cost (95% CI: 0.3, 18.0; p = 0.04), all compared to LIS enrollees.
Conclusions: Despite providing substantial financial assistance with prescription drug costs, the LIS is under-utilized among beneficiaries with chronic conditions requiring routine medication use. As policy makers discuss Part D reforms to address rising out-of-pocket drug costs, they should consider strategies to increase participation in existing programs that alleviate cost burdens among low-income Medicare beneficiaries.
Keywords: Medicare Part D; diabetes mellitus; drug costs; health expenditures; older adults; out-of-pocket costs; poverty.
© 2022 Health Research and Educational Trust.
Similar articles
-
Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.JAMA Health Forum. 2024 Feb 2;5(2):e235152. doi: 10.1001/jamahealthforum.2023.5152. JAMA Health Forum. 2024. PMID: 38306091 Free PMC article.
-
Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.J Manag Care Spec Pharm. 2024 Mar 1;30(3):269-278. doi: 10.18553/jmcp.2023.23153. Epub 2023 Dec 23. J Manag Care Spec Pharm. 2024. PMID: 38140901 Free PMC article.
-
Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.J Am Coll Cardiol. 2023 Apr 18;81(15):1491-1501. doi: 10.1016/j.jacc.2023.02.002. Epub 2023 Feb 20. J Am Coll Cardiol. 2023. PMID: 37045519 Free PMC article.
-
Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.Am J Health Syst Pharm. 2007 Aug 1;64(15 Suppl 10):S3-6; quiz S21-S23. doi: 10.2146/ajhp070252. Am J Health Syst Pharm. 2007. PMID: 17646551 Review.
-
Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.Res Social Adm Pharm. 2020 Jun;16(6):736-745. doi: 10.1016/j.sapharm.2019.08.031. Epub 2019 Aug 17. Res Social Adm Pharm. 2020. PMID: 31445986 Review.
Cited by
-
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.Curr Atheroscler Rep. 2023 Dec;25(12):1113-1127. doi: 10.1007/s11883-023-01180-5. Epub 2023 Dec 18. Curr Atheroscler Rep. 2023. PMID: 38108997 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
